Oramed Pharmaceuticals Analyst Ratings
Oramed Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/17/2023 | — | HC Wainwright & Co. | Downgrades | Buy → Neutral | |
| 01/12/2023 | — | Canaccord Genuity | Downgrades | Buy → Hold | |
| 05/16/2022 | 1233.33% | Aegis Capital | $35 → $30 | Maintains | Buy |
| 02/18/2022 | 788.89% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 11/30/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/29/2021 | 1322.22% | HC Wainwright & Co. | $17 → $32 | Maintains | Buy |
| 11/02/2021 | 1455.56% | Aegis Capital | $20 → $35 | Maintains | Buy |
| 07/29/2021 | 1233.33% | Canaccord Genuity | $27 → $30 | Maintains | Buy |
| 06/08/2021 | 788.89% | Aegis Capital | $12 → $20 | Maintains | Buy |
| 04/20/2021 | 1100% | Canaccord Genuity | → $27 | Initiates Coverage On | → Buy |
| 02/09/2021 | 922.22% | National Securities Corporation | → $23 | Initiates Coverage On | → Buy |
| 01/27/2021 | 433.33% | Aegis Capital | $6 → $12 | Maintains | Buy |
| 07/13/2020 | 655.56% | HC Wainwright & Co. | $16 → $17 | Reiterates | → Buy |
| 06/22/2020 | 611.11% | HC Wainwright & Co. | $20 → $16 | Maintains | Buy |
| 09/11/2019 | 211.11% | Ladenburg Thalmann | → $7 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 01/17/2023 | — | HC Wainwright & Co. | 降级 | 买入 → 中性 | |
| 01/12/2023 | — | Canaccord Genu | 降级 | 买入 → 持有 | |
| 05/16/2022 | 1233.33% | 宙斯盾资本 | 35 美元 → 30 美元 | 维护 | 买 |
| 02/18/2022 | 788.89% | 坎托·菲茨杰拉德 | → 20 美元 | 开启覆盖范围 | → 超重 |
| 11/30/2021 | 1322.22% | HC Wainwright & Co. | 17 美元 → 32 美元 | 维护 | 买 |
| 11/29/2021 | 1322.22% | HC Wainwright & Co. | 17 美元 → 32 美元 | 维护 | 买 |
| 11/02/2021 | 1455.56% | 宙斯盾资本 | 20 美元 → 35 美元 | 维护 | 买 |
| 07/29/2021 | 1233.33% | Canaccord Genu | 27 美元 → 30 美元 | 维护 | 买 |
| 06/08/2021 | 788.89% | 宙斯盾资本 | 12 美元 → 20 美元 | 维护 | 买 |
| 04/20/2021 | 1100% | Canaccord Genu | → 27 美元 | 开启覆盖范围 | → 购买 |
| 02/09/2021 | 922.22% | 国家证券公司 | → 23 美元 | 开启覆盖范围 | → 购买 |
| 01/27/2021 | 433.33% | 宙斯盾资本 | 6 美元 → 12 美元 | 维护 | 买 |
| 07/13/2020 | 655.56% | HC Wainwright & Co. | 16 美元 → 17 美元 | 重申 | → 购买 |
| 06/22/2020 | 611.11% | HC Wainwright & Co. | 20 美元 → 16 美元 | 维护 | 买 |
| 09/11/2019 | 211.11% | 拉登堡塔尔曼 | → 7 美元 | 开启覆盖范围 | → 购买 |
What is the target price for Oramed Pharmaceuticals (ORMP)?
Oramed Pharmicals（ORMP）的目标价格是多少？
The latest price target for Oramed Pharmaceuticals (NASDAQ: ORMP) was reported by HC Wainwright & Co. on January 17, 2023. The analyst firm set a price target for $0.00 expecting ORMP to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 于2023年1月17日公布了Oramed Pharmicals（纳斯达克股票代码：ORMP）的最新目标股价。这家分析公司将目标价设定为0.00美元，预计ORMP将在12个月内降至-100.00％（可能下跌-100.00％）。去年，有4家分析公司公布了评级。
What is the most recent analyst rating for Oramed Pharmaceuticals (ORMP)?
Oramed Pharmicals（ORMP）的最新分析师评级是多少？
The latest analyst rating for Oramed Pharmaceuticals (NASDAQ: ORMP) was provided by HC Wainwright & Co., and Oramed Pharmaceuticals downgraded their neutral rating.
Oramed Pharmicals（纳斯达克股票代码：ORMP）的最新分析师评级由HC Wainwright & Co. 提供，Oramed Pharmicals下调了中性评级。
When is the next analyst rating going to be posted or updated for Oramed Pharmaceuticals (ORMP)?
Oramed Pharmicals（ORMP）的下一个分析师评级将在何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Oramed Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Oramed Pharmaceuticals was filed on January 17, 2023 so you should expect the next rating to be made available sometime around January 17, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与Oramed Pharmicals的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。Oramed Pharmicals的最新评级是在2023年1月17日公布的，因此你应该预计下一个评级将在2024年1月17日左右公布。
Is the Analyst Rating Oramed Pharmaceuticals (ORMP) correct?
分析师评级 Oramed Pharmicals（ORMP）是否正确？
While ratings are subjective and will change, the latest Oramed Pharmaceuticals (ORMP) rating was a downgraded with a price target of $0.00 to $0.00. The current price Oramed Pharmaceuticals (ORMP) is trading at is $2.25, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Oramed Pharmicals（ORMP）评级被下调，目标价为0.00美元至0.00美元。Oramed Pharmicals（ORMP）目前的交易价格为2.25美元，超出了分析师的预期区间。